Literature DB >> 30209097

Clare Lambert, Constadina Panagiotopoulos, Jana Davidson, Ran D Goldman.   

Abstract

Year:  2018        PMID： 30209097      PMCID： PMC6135139     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  30 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 3.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.

Authors:  Christoph U Correll
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-01       Impact factor: 8.829

4.  Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth.

Authors:  Rebecca Ronsley; Kamini Raghuram; Jana Davidson; Constadina Panagiotopoulos
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-05

5.  Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population.

Authors:  Nikita Arora; Sandra Knowles; Tara Gomes; Muhammad M Mamdani; David N Juurlink; Corine Carlisle; Mina Tadrous
Journal:  Can J Psychiatry       Date:  2016-07-10       Impact factor: 4.356

6.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

7.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Authors:  Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

8.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.

Authors:  Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-11       Impact factor: 8.829

9.  Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment.

Authors:  Yan Xu; Duc Nguyen; Jana Davidson; Constadina Panagiotopoulos
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2012-11

10.  A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.

Authors:  Magali Haas; Alan S Unis; Jorge Armenteros; Margaret D Copenhaver; Jorge A Quiroz; Stuart F Kushner
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-12       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.